Company news
Immucell Corporation (NASDAQ:ICCC) news
Every Immucell Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
August 13, 2026
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
July 9, 2026
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
May 14, 2026
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
May 7, 2026
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
April 13, 2026
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
April 8, 2026
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
March 18, 2026
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
March 4, 2026
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
February 18, 2026
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
January 8, 2026
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
January 7, 2026
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
December 24, 2025
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025
November 13, 2025
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025
November 6, 2025
ImmuCell Announces Onboarding of New CEO and Related Management Changes
November 4, 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
October 7, 2025
ImmuCell Announces Selection of its Next President and CEO
September 29, 2025
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025
August 14, 2025
ImmuCell Announces Bank Debt Refinancing
August 12, 2025
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
August 7, 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
July 9, 2025
ImmuCell Embarks on CEO Succession Planning Process
June 25, 2025
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
June 5, 2025
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
May 14, 2025
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
May 12, 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
April 8, 2025
ImmuCell Hires Chief Financial Officer
April 7, 2025
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®
April 2, 2025
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
February 25, 2025
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
February 20, 2025
ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses
January 16, 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
January 9, 2025
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
November 13, 2024
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024
November 7, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
October 8, 2024
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
August 13, 2024
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
August 7, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
July 9, 2024
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®
June 5, 2024
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
May 14, 2024
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024
May 8, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
April 9, 2024
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
February 27, 2024
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
February 16, 2024
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023
January 8, 2024
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023
November 13, 2023
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
November 7, 2023
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
October 5, 2023
ImmuCell Announces Submission of CMC Technical Section to the FDA
August 29, 2023
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
August 10, 2023